DEF: Establishment Labs Annual Meeting Proxy Statement

Establishment Labs Holdings Inc. announces its 2026 Annual Meeting of Shareholders, scheduled for May 22, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.

Summary

• The company is holding its 2026 Annual Meeting of Shareholders on May 22, 2026, at 1:00 PM Eastern Time, conducted exclusively online.
• Shareholders of record as of April 2, 2026, are eligible to vote.
• Key items of business include the election of six director nominees, an advisory vote on executive compensation, and ratification of the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for fiscal year 2026.
• The Board of Directors recommends a vote FOR all proposed items.
• The meeting will be held virtually at www.virtualshareholdermeeting.com/ESTA2026.
• Shareholders can vote via internet, telephone, or mail prior to the meeting, or online during the virtual meeting.
• Juan Jose Chacn Quiros, founder, is not standing for re-election and will retire from the Board at this meeting, reducing the Board size to six directors.
• The company's revenue for the year ended December 31, 2025, was $211.1 million, an increase of 27.2% from $166.0 million in 2024.
• Net losses for the year ended December 31, 2025, were $51.1 million, an improvement from $84.6 million in 2024.
• Cash balance as of December 31, 2025, was $75.6 million.
• The company has a share ownership policy for non-employee directors requiring them to own shares valued at $150,000, with all currently compliant.
• The company has a Senior Leader Share Ownership Policy requiring the CEO to own shares valued at six times his base salary and other executives at one times their base salary.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, as it outlines standard corporate governance procedures and executive compensation plans, with positive trends in revenue growth and reduced net losses, but no significant new strategic announcements or financial performance exceeding expectations.

Positives

• Revenue increased by 27.2% to $211.1 million for the year ended December 31, 2025.
• Net losses decreased to $51.1 million for the year ended December 31, 2025, from $84.6 million in the prior year.
• The company maintains a strong cash balance of $75.6 million as of December 31, 2025.
• All non-employee directors are currently compliant with the share ownership policy.
• The Compensation Committee engaged Alpine Rewards in late 2025 to evaluate executive and non-employee director compensation programs for 2026.
• Over 99% of votes cast at the 2025 Annual Meeting supported the say-on-pay proposal, indicating shareholder confidence in the executive compensation program.
• The company's independent registered public accounting firm, CBIZ CPAs P.C., has served the company since 2016 and is proposed for ratification for 2026.

Negatives

• The company reported net losses of $51.1 million for the year ended December 31, 2025.
• Two Form 4s and one Form 4 were filed late in March 2025, and three Form 4s were filed late in April 2025, related to tax withholdings and annual performance grants for Messrs. Denhoy, Mansbach, and Caldini.
• One Form 4 was filed late in January 2026, reporting a grant to Mr. Chacn Quirs for consulting services post-retirement.
• The company recorded revenue of $1.2 million for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of former CEO Juan Jose Chacn Quirs, with outstanding receivables of $0.4 million as of December 31, 2025.
• The company paid Dr. Chacn Quirs (brother of former CEO) approximately $0.1 million for services rendered in 2025 under an agreement for training services.

Risks

• The company is subject to Section 16(a) reporting requirements, and there were instances of late filings in 2025 and early 2026.
• The company has related party transactions, including sales to a company owned by a family member of the former CEO and services provided by the former CEO's brother.
• The company's executive compensation program is designed to link NEO interests with shareholders, but potential risks related to excessive or unreasonable risk-taking are regularly monitored.
• The company's Memorandum and Articles of Association limit director liability, but this does not eliminate all potential risks associated with director service.

Future Outlook

The company is holding its 2026 Annual Meeting of Shareholders on May 22, 2026, to elect directors, approve executive compensation, and ratify the appointment of its independent auditor. The Board of Directors recommends a vote FOR all proposals. The company's revenue increased by 27.2% in 2025, and net losses decreased.

Management Comments

• We cordially invite you to attend the 2026 annual meeting of shareholders...
• We believe that sound corporate governance is fundamental to the overall success of Establishment Labs...
• We believe that granting equity and cash compensation to members of the Board represents an effective tool to attract, retain, and reward directors who are not Establishment Labs employees.
• We believe that severance protections, particularly in the context of the uncertainty surrounding any potential change in control transaction, play a valuable role in attracting and retaining quality executive officers.
• We believe our 2025 compensation programs do not create risks that are reasonably likely to have a material adverse effect on our Company.

Industry Context

StockSavvy.ai notes that Establishment Labs' proxy statement details its approach to corporate governance, executive compensation, and director nominations, which are standard practices for publicly traded companies in the medical technology and aesthetics sectors. The focus on aligning executive compensation with long-term shareholder value through equity awards and performance-based incentives is consistent with industry trends.

Comparison to Industry Standards

• The company's board composition includes a majority of independent directors (4 out of 7), aligning with Nasdaq listing standards.
• The executive compensation structure, utilizing a mix of base salary, annual incentives, and long-term equity awards (50% stock options, 50% RSUs), is a common practice in the medical device industry to incentivize performance and retention.
• The peer group used for compensation benchmarking includes companies like Inspire Medical Systems, OrthoPediatrics Corp., and STAAR Surgical Company, which are comparable medical device companies.
• The company's share ownership policy for directors and executives is a standard corporate governance practice aimed at aligning management and shareholder interests.

Management Changes

Corporate Governance

Related Party Transactions

• Revenue of $1.2 million recorded for product sales to Herramientas Medicas, S.A., a distribution company owned by a family member of Juan Jose Chacn Quirs (former CEO and Board member). Accounts receivable from this company were $0.4 million as of December 31, 2025.
• Agreement with Dr. Chacn Quirs (brother of former CEO) for training services at an hourly rate of $531, with options granted to purchase 22,068 common shares vesting over four years. Approximately $0.1 million paid to Dr. Chacn Quirs in 2025 for services rendered.

Stakeholder Impact

• Shareholders: Will vote on director elections, executive compensation, and auditor ratification. The company's financial performance (revenue growth, reduced losses) and governance practices are key considerations.
• Employees: Executive compensation is tied to performance, and all employees are eligible for the 401(k) plan. Share ownership policies aim to align executive interests with the company's success.
• Management: Executive compensation is structured to incentivize long-term value creation and retention, with severance benefits provided under specific termination conditions.
• Auditors: CBIZ CPAs P.C. is proposed for ratification as the independent registered public accounting firm for fiscal year 2026.

Next Steps

• Shareholders are urged to submit their votes for the Annual Meeting.
• The company will announce preliminary voting results at the Annual Meeting and disclose final results on a Form 8-K filing with the SEC within four business days after the meeting.
• Shareholder proposals for the 2027 annual meeting must be submitted by December 11, 2026.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual shareholder meeting and does not contain new material financial information or strategic developments that would warrant a change in investment recommendation. While revenue growth and reduced losses are positive, the company continues to report net losses. The focus remains on governance and compensation, which are standard disclosures. Investors should await further operational and financial updates.

Keywords

Establishment Labs Holdings Inc., Proxy Statement, Annual Meeting, Shareholder Meeting, Board of Directors, Executive Compensation, Independent Auditor, Corporate Governance, Director Election, SEC Filing, Schedule 14A